UNSPSC 51141576: Valproate pivoxil

This classification denotes an anticonvulsant agent with the molecular formula C14H26O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9F5A05A29T, chemically known as hydroxymethyl 2-propylvalerate, pivalate but generally known as valproate pivoxil, which bears US NIH Compound Identifier 71160. European Medicines Agency schedules Valproate pivoxil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00013MIG. The term VALPROATE PIVOXIL is an International Non-Proprietary Name.

Most nations schedule valproate pivoxil under HS 29159080 and SITC 51377. As of Q4 2014, VALPROATE PIVOXIL remains the US FDA Preferred Term for this commodity. Valproate pivoxil bears US NLM identifiers UMLS ID C2349103 and NCI Concept Code C72875. SMILES: O(C(=O)C(CCC)CCC)COC(=O)C(C)(C)C.

UNSPSC 51141576 Valproate pivoxil is a Commodity code that nominally identifies a specific anticonvulsant pharmaceutical, but recent state and local procurement activity under this code shows significant scope mismatch. The three most recent solicitations tagged to the code involve naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and OTC products—none of which are valproate pivoxil. The code shows no substantive activity aligned with its stated product name in the recent opportunities block.

The issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance serving state and local governments across Minnesota and Oregon). Seminole County's IFB60459723LAS solicits naloxone and drug deactivation systems with an IFB response deadline of July 26, 2023; the Texas HHS RFI HHS0017013 explores direct-to-manufacturer prescription capabilities with an April 3, 2026 response date; and the Minnesota MMCAP RFP S1070000015802 seeks generic pharmaceuticals and OTC products through authorized wholesalers with a March 26, 2026 proposal deadline. The mismatch between the code's pharmaceutical name and the actual scope of recent solicitations suggests the code may be incorrectly applied to general pharmaceutical procurement or that valproate pivoxil activity at the state and local level does not appear in current opportunities. Firms targeting pharmaceutical supply to state and local governments should verify code assignment with issuing agencies before pursuing opportunities tagged to 51141576.